Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33482247

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)(☆).

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Ann Oncol
Publication date
2021 Apr
First author
Casali PG

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Oncol. 2021 Apr;32(4):434-436. doi: 10.1016/j.annonc.2021.01.073.
    note
    Source null
    related pmid
    33524476
    relationship
    Comment in

Authors and identifiers

  1. name
    Casali PG
    type
    Author
  2. name
    Le Cesne A
    type
    Author
  3. name
    Velasco AP
    type
    Author
  4. name
    Kotasek D
    type
    Author
  5. name
    Rutkowski P
    type
    Author
  6. name
    Hohenberger P
    type
    Author
  7. name
    Fumagalli E
    type
    Author
  8. name
    Judson IR
    type
    Author
  9. name
    Italiano A
    type
    Author
  10. name
    Gelderblom H
    type
    Author
  11. name
    Penel N
    type
    Author
  12. name
    Hartmann JT
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Casali PG
    type
    Author
  2. name
    Le Cesne A
    type
    Author
  3. name
    Velasco AP
    type
    Author
  4. name
    Kotasek D
    type
    Author
  5. name
    Rutkowski P
    type
    Author
  6. name
    Hohenberger P
    type
    Author
  7. name
    Fumagalli E
    type
    Author
  8. name
    Judson IR
    type
    Author
  9. name
    Italiano A
    type
    Author
  10. name
    Gelderblom H
    type
    Author
  11. name
    Penel N
    type
    Author
  12. name
    Hartmann JT
    type
    Author
bibliography ids
  1. nci-bib-317ad53521fcbaa5c5abcaa1
book metadata
content sha256
97f3da91c0806ac3b84bb17afb7565e4063283a2aa9f78fe58cd3734f8fd68a0
document type
citation
dois
  1. 10.1016/j.annonc.2021.01.004
electronic publication date
display
2021 Jan 19
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33482247
immutable id
pubmed:33482247@97f3da91c0806ac3b84bb17afb7565e4063283a2aa9f78fe58cd3734f8fd68a0
journal
abbreviation
Ann Oncol
issn electronic
1569-8041
issn print
0923-7534
issue
4
name
Annals of oncology : official journal of the European Society for Medical Oncology
nlm unique id
9007735
pages
533-541
volume
32
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Oncol. 2021 Apr;32(4):434-436. doi: 10.1016/j.annonc.2021.01.073.
    note
    Source null
    related pmid
    33524476
    relationship
    Comment in
outcomes validated
false
pmid
33482247
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
8402f0bea4989ad94c0db92381bd2c4697c542d032ec9cfffbe61b955fec791e
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2021 Apr
precision
month
year
2021
publication types
  1. Journal Article
  2. Multicenter Study
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33482247/
title
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)(☆).

Preserved source evidence · Not medical advice